<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03354936</url>
  </required_header>
  <id_info>
    <org_study_id>2017-A00699-44</org_study_id>
    <nct_id>NCT03354936</nct_id>
  </id_info>
  <brief_title>ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint)</brief_title>
  <acronym>OncoVIHAC</acronym>
  <official_title>A Multicenter Observational Cohort for HIV Infected Patients With a Cancer Treated by Immune-Checkpoint Inhibitors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pitié-Salpêtrière Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bicetre Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multicenter, Observational, National Cohort for HIV Infected Patients with a Cancer treated
      by Immune-Checkpoint Inhibitors (ICPi) for less than one month or to be treated with an ICPi
      such as anti-PD-1 or anti-PDL-1 or anti-CTLA4, monitored in some French hospitals .

      The objective of the study is to assess the safety of these new agents in HIV-infected
      patients.

      As an observatory, the number of participants planned is not predetermined: the aim is to
      include for 2 years any participant infected with HIV and having a cancer treated by ICPi in
      one of the centers that have agreed to participate.

      50 participants will be recruited for Substudy &quot;OncoVIRIM&quot; during the study period
      (regardless of tumor type or ICPi type); 8 or 9 time points (blood samples) will be scheduled

      The cohort &quot; ANRS CO24 OncoVIHAC &quot; is declared to authorities like category 2 research .

      No intervention in the observatory, a collection of data will be carried out in M0, M6, M12,
      M18 and M24.

      For the physiopathological Substudy OncoVIRIM : Blood samples will be collected to constitute
      cell bank, plasma bank, serum bank, DNA bank in order to meet the objectives of this substudy
      and possibly for complementary research
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective To evaluate clinical and biological safety of the use of immune checkpoint
      inhibitors in HIV infected patients with cancer treated by Immune-Checkpoint Inhibitors
      (ICPi).

      Secondary objectives

        -  To evaluate evolution of HIV immunological and virological data in HIV infected patients
           with cancer treated by Immune-Checkpoint Inhibitors (ICPi):

        -  HIV-RNA plasma viral load

        -  Evolution of CD4+ and CD8+ T cells counts, CD4/CD8 ratio

        -  To assess the efficacy endpoint : progression-free survival, overall survival rate at 1
           year and 2 years.

        -  Potential Modification of antiretroviral therapy

      Secondary objectives of the Physiopathological Substudy &quot;OncoVIRIM&quot; (Limited to a few
      clinical centers with a suitable technical tray) :

        -  To evaluate response to ICPi treatment according to RECIST criteria (solid tumor) and
           CHESON criteria (lymphoma)

        -  Other immunological and virological explorations on HIV :

        -  To evaluate low level HIV replication and size of the HIV reservoir

        -  To evaluate effects of ICPi on HIV-specific immune responses

        -  To show the effects of ICPi on HIV-related immune alterations such as T cell
           differentiation, T cell activation/exhaustion and systemic inflammation

        -  To demonstrate an effect on other viruses-specific T cells and viremia (EBV, CMV, HHV-8,
           HBV et HCV (if co-infected)

        -  To better understand the pathophysiology of ICPi-related immune adverse effects,
           particularly the development of infraclinical auto-immunity : monitoring of
           autoantibodies and analysis of changes in B cell antibodies repertoires

        -  To find immune biomarkers predictive for clinical response to ICPi, MHC class I and II
           in particular and description of any gene of interest in the context of ICPi treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2018</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Incidence of clinical and biological adverse events occurring with ICPi treatment during the study period</measure>
    <time_frame>4.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immuno-virological evolution</measure>
    <time_frame>between Month0 and Month24</time_frame>
    <description>HIV-RNA plasma viral load copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immuno-virological evolution</measure>
    <time_frame>between Month0 and Month 24</time_frame>
    <description>CD4+ and CD8+ T cells counts /mm3 and %, CD4/CD8 ratio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease status</measure>
    <time_frame>at Month12 and at Month24</time_frame>
    <description>Overall response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free survival</measure>
    <time_frame>at Month6, Month12, Month18, Month24</time_frame>
    <description>Progression-Free survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Physiopathological Substudy &quot;OncoVIRIM&quot; : Objective Response Rate (OPR)</measure>
    <time_frame>At following cures cycles according to the type of treatment : Cycle1 (Week0), Cycle2 (Week2 or Week3), Cycle3 (Week4 or Week6), Cycle9 (Week16) or Cycle9 (Week24), Cycle 15(Week28), Cycle18 (Week52), Cycle27 (Week52), Cycle36 (Week104), Month6, Month12</time_frame>
    <description>Objective response rate of patient tumor with ICPi treatment according to RECIST criteria (solid tumor) et CHESON criteria (lymphoma).
The cycles of cures concerned according to the type of treatment :
Nivolumab with a cure cycle length of 2 weeks : Cycle1(Week0), Cycle2 (Week2), Cycle3 (Week4), Cycle9 (Week16), Cycle15 (Week28), Cycle27 (Week52), Cycle51 (Week100)
Pembrolizumab with a cure cycle length of 3 weeks : Cycle1 (Week0), Cycle2 (Week3), Cycle3 (Week6), Cycle9 (Week24), Cycle18 (Week52), Cycle36 (Week104)
Ipilimumab with a cure cycle length of 3 weeks : Cycle1 (Week0), Cycle2(Week3), Cycle3 (Week6), Cycle4 (Week9), Month6, Month12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Physiopathological Substudy &quot;OncoVIRIM&quot; : Detailed Immunological and Virological Evolution</measure>
    <time_frame>At following cures cycles according to the type of treatment : Cycle1 (Week0), Cycle2 (Week2 or Week3), Cycle3 (Week4 or Week6), Cycle9 (Week16) or Cycle9 (Week24), Cycle 15(Week28), Cycle18 (Week52), Cycle27 (Week52), Cycle36 (Week104), Month6, Month12</time_frame>
    <description>- Low level of HIV-RNA plasma viral load (ultrasensitive assay), HIV-DNA viral load in PBMCs (peripheral blood mononuclear cells)
The cycles of cures concerned according to the type of treatment :
Nivolumab with a cure cycle length of 2 weeks : Cycle1 (Week0), Cycle2 (Week2), Cycle3 (Week4), Cycle9 (Week16), Cycle 15(Week28), Cycle27 (Week52), Cycle51 (Week100), in case of treatment stopped and in case of immunological adverse event.
Pembrolizumab with a cure cycle length of 3 weeks : Cycle1 (Week0), Cycle2 (Week3), Cycle3 (Week6), Cycle9 (Week24), Cycle18 (Week52), Cycle36 (Week104) in case of treatment stopped and in case of immunological adverse event.
Ipilimumab with a cure cycle length of 3 weeks : Cycle1 (Week0), Cycle2(Week3), Cycle3 (Week6), Cycle4 (Week9), Month 6, Month 12, in case of treatment stopped and in case of immunological adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Physiopathological Substudy &quot;OncoVIRIM&quot; : Detailed Immunological and Virological Evolution</measure>
    <time_frame>At following cures cycles according to the type of treatment : Cycle1 (Week0), Cycle2 (Week2 or Week3), Cycle3 (Week4 or Week6), Cycle9 (Week16) or Cycle9 (Week24), Cycle 15(Week28), Cycle18 (Week52), Cycle27 (Week52), Cycle36 (Week104), Month6, Month12</time_frame>
    <description>- Anti-HIV Specific Immune Responses T cell (polyfunctionality and expression of immune checkpoints)
The cycles of cures concerned according to the type of treatment :
Nivolumab with a cure cycle length of 2 weeks : Cycle1 (Week0), Cycle2 (Week2), Cycle3 (Week4), Cycle9 (Week16), Cycle 15(Week28), Cycle27 (Week52), Cycle51 (Week100), in case of treatment stopped and in case of immunological adverse event.
Pembrolizumab with a cure cycle length of 3 weeks : Cycle1 (Week0), Cycle2 (Week3), Cycle3 (Week6), Cycle9 (Week24), Cycle18 (Week52), Cycle36 (Week104) in case of treatment stopped and in case of immunological adverse event.
Ipilimumab with a cure cycle length of 3 weeks : Cycle1 (Week0), Cycle2(Week3), Cycle3 (Week6), Cycle4 (Week9), Month 6, Month 12, in case of treatment stopped and in case of immunological adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Physiopathological Substudy &quot;OncoVIRIM&quot; : Detailed Immunological and Virological Evolution</measure>
    <time_frame>At following cures cycles according to the type of treatment : Cycle1 (Week0), Cycle2 (Week2 or Week3), Cycle3 (Week4 or Week6), Cycle9 (Week16) or Cycle9 (Week24), Cycle 15(Week28), Cycle18 (Week52), Cycle27 (Week52), Cycle36 (Week104), Month6, Month12</time_frame>
    <description>- Systemic inflammation markers and markers of T cell activation, exhaustion, and differentiation
The cycles of cures concerned according to the type of treatment :
Nivolumab with a cure cycle length of 2 weeks : Cycle1 (Week0), Cycle2 (Week2), Cycle3 (Week4), Cycle9 (Week16), Cycle 15(Week28), Cycle27 (Week52), Cycle51 (Week100), in case of treatment stopped and in case of immunological adverse event.
Pembrolizumab with a cure cycle length of 3 weeks : Cycle1 (Week0), Cycle2 (Week3), Cycle3 (Week6), Cycle9 (Week24), Cycle18 (Week52), Cycle36 (Week104) in case of treatment stopped and in case of immunological adverse event.
Ipilimumab with a cure cycle length of 3 weeks : Cycle1 (Week0), Cycle2(Week3), Cycle3 (Week6), Cycle4 (Week9), Month 6, Month 12, in case of treatment stopped and in case of immunological adverse event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Physiopathological Substudy &quot;OncoVIRIM&quot; :</measure>
    <time_frame>between Month0 and Month24</time_frame>
    <description>Incidence of autoimmune complications and changes in antibodies repertoires of B cell in case of immunological adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For Physiopathological Substudy &quot;OncoVIRIM&quot; : Gene sequencing</measure>
    <time_frame>Week0</time_frame>
    <description>Gene sequencing whose interest appears to be major in the responses / adverse effects of ICPi, especially MHC class I and II</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>HIV Infected Patients With Cancer Treated by ICPi</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Blood samples will be collected to constitute cell bank, plasma bank, serum bank, DNA bank in order to meet the objectives of this substudy and possibly for complementary research</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      No intervention in the observatory, a collection of data will be carried out in M0, M6, M12,
      M18 and M24.

      For the physiopathological Substudy OncoVIRIM : Blood samples will be collected to constitute
      cell bank, plasma bank, serum bank, DNA bank in order to meet the objectives of this substudy
      and possibly for complementary research.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV Infected Patients with a Cancer treated by Immune-Checkpoint Inhibitors.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Study Population for Cohort

        Inclusion criteria :

          -  Age ≥ 18 years

          -  Documented HIV-1 infection treated or untreated with antiretrovirals

          -  Cancer histologically and /or cytologically proven

          -  Person treated for less than 30 days or who should be treated with anti-PD-1 or
             anti-PDL-1 or anti-CTLA4 according to current recommendations

          -  Signed informed consent

        Exclusion Criteria

        - Subject participating in clinical trials &quot;CHIVA 2&quot; (Lung Cancer- IFCT) and &quot;HANOVRE&quot;
        (Hodgkin's disease - LYSA)

        Study Population for the Physiopathological Substudy &quot;OncoVIRIM&quot;:

        Inclusion criteria:

          -  Participant included in the observatory

          -  Stable antiretroviral therapy (ART) with controlled HIV-RNA plasma viral load ≤ 50
             copies/mL

          -  Beneficiary of a Social Security program (State Medical Aid or AME is not a Social
             Security program), article L1121-11 of the Public health code…

          -  Signed informed consent.

        Non Inclusion Criteria

          -  Brain or lung radiotherapy &lt; 30 days

          -  Transplant organ or bone marrow transplant

          -  Corticosteroid &gt; 10 mg per day

          -  Participant who started ICPi treatment prior to inclusion in the observatory
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe SPANO, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GH Pitié-Salpêtrière-Charles Foix</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier LAMBOTTE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bicêtre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joséphine Anna TINE</last_name>
    <phone>+33 (0)1 42 16 42 88</phone>
    <email>josephine-anna.tine@iplesp.upmc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Safa LASSOUED</last_name>
    <phone>+33 (0)1 42 16 42 88</phone>
    <email>safa.lassoued@iplesp.upmc.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Immunologie - Hôpital Felix Guyon</name>
      <address>
        <city>La Réunion</city>
        <state>Saint-Denis</state>
        <zip>97405</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine GAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Catherine GAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie Oncologie - Centre Hospitalier du Pays d'Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry ALLEGRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry ALLEGRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de pneumologie - Hôpital Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure BELMONT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laure BELMONT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Onco-Hématologie Immunodépression - Hôpital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles PICHANCOURT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gilles PICHANCOURT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine CHIROUZE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Catherine CHIROUZE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pôle de Médecine 2 - Centre Hospitalier Andrée Rosemon</name>
      <address>
        <city>Cayenne</city>
        <zip>97306</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Béatrice VIRJOGHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine interne - Hôpital Antoine Béclère</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François BOUE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-François BOUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'hématologie - Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile MOLUCON-CHABROT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cécile MOLUCON-CHABROT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales - Hôpital Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine JACOMET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christine JACOMET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Immunologie Clinique - Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Daniel LELIEVRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Daniel LELIEVRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine interne - Centre Hospitalier Intercommunal</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Valérie GARRAIT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Valérie GARRAIT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de pneumologie - Centre Hospitalier Intercommunal</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle MONNET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle MONNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hémopathies Lymphoïdes - Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne HAIOUN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Corinne HAIOUN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Oncologie Médicale - Centre Hospitalier Intercommunal</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle COJEAN-ZELEK</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle COJEAN-ZELEK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine interne et Maladies infectieuses - Hôpital André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alix GREDER-BELAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alix GREDER-BELAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'hématologie et oncologie - Hôpital André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline BESSON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Caroline BESSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine interne-Immunologie clinique - Hôpital Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94276</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier LAMBOTTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier LAMBOTTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales - Hôpital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent COTTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent COTTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ambulatoire-Hôpital de Jour - Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François MOULIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-François MOULIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'hématologie-Cisih - Hôpital Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13274</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle POIZOT-MARTIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle POIZOT-MARTIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de dermatologie - Hôpital St Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank TOLLINCHI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frank TOLLINCHI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie - Hôpital St Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina AUDOLY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christina AUDOLY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgie Urologique et Tranplantation Rénale - Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric LECHEVALLIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric LECHEVALLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie médicale - Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Laurent DEVILLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Laurent DEVILLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service dermatologie/vénéréologie - Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques GROB, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Jacques GROB, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'oncologie multidiscliplinaire - Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent GREILLIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent GREILLIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne - Centre Hospitalier de Martigues</name>
      <address>
        <city>Martigues</city>
        <zip>13695</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolande COHEN VALENSI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rolande COHEN VALENSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales - Hôpital Gui de Chauliac</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain MAKINSON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alain MAKINSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Dermatologie - Hôpital l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra PICARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandra PICARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de médecine interne Cancérologie - Hôpital l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric ROSENTHAL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric ROSENTHAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales - Hôpital l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alissa NAQVI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alissa NAQVI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses - Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karine LACOMBE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Karine LACOMBE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Infectiologie - Hôpital de l'Hôtel-Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75101</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique SALMON-CERON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique SALMON-CERON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'immuno-pathologie clinique - Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence GERARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurence GERARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses - Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane PONSCARME, MD</last_name>
    </contact>
    <investigator>
      <last_name>Diane PONSCARME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servide de Dermatologie - Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Céleste LEBBE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Céleste LEBBE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie Médicale - Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Philippe SPANO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Philippe Spano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales - Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine KATLAMA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christine KATLAMA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Hématologie Clinique - Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain CHOQUET</last_name>
    </contact>
    <investigator>
      <last_name>Sylvain CHOQUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazdan YAZDANPANAH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yazdan YAZDANPANAH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service d'Immunologie Clinique - Hôpital européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence WEISS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurence WEISS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Cancérologie Médicale - Hôpital européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75909</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane OUDARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stéphane OUDARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de pneumologie - Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armelle LAVOLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Armelle LAVOLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales - Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75971</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles PIALOUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gilles PIALOUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de pneumologie - Hôpital Yves Le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gwenaëlle LE GARFF, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gwenaëlle LE GARFF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Médecine interne - Maladies Infectieuses - Hôpital Yves Le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corinne DANIEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Corinne DANIEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service Oncologie Hématologie - Hôpital Yves Le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corinne ALLEAUME, MD</last_name>
    </contact>
    <investigator>
      <last_name>Corinne ALLEAUME, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Saint Etienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne FRESARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne FRESARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre FOURNEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre FOURNEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Trait d'Union - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Laure BATARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marie-Laure BATARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne - Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David ZUCMAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>David ZUCMAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie - Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Louis COUDERC, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Louis COUDERC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Interne - Hôpital d'Instruction des Armées Saint Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83041</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre DE JAUREGUIBERRY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre DE JAUREGUIBERRY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et Tropicales - Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre DELOBEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre DELOBEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Maladies Infectieuses et du Voyageur - Centre Hospitalier de Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faïza AJANA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Faïza AJANA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département d'Innovation Thérapeutique et d'Essais Précoces - Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélien MARABELLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurélien MARABELLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>November 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

